首页> 外文期刊>Platelets >Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS
【24h】

Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

机译:炎症状态不会影响有效的P2Y12抑制剂在ACS中的抗血小板疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Inflammation leads to atherosclerosis and acute coronary syndromes (ACS). We performed a prospective, observational study to assess association between the concentrations of inflammatory markers (high sensitivity C-reactive protein, hsCRP; high sensitivity interleukin6, hsIL-6; soluble CD40 ligand, sCD40 L) and platelet reactivity in 338 patients with ACS treated with ticagrelor and prasugrel. We also assessed whether hsCRP, hsIL-6, and sCD40 L are associated with standard inflammatory markers (white blood cell [WBC] and fibrinogen), and whether they differ according to patient diabetic status and pre-treatment with statins. Concentrations of hsCRP and concentrations of hsIL-6 and sCD40 L were assessed using turbidimetric assay and enzyme-linked immunosorbent assay, respectively. Platelet reactivity was measured using multiple electrode aggregometry. There was only a weak inverse correlation between hsIL-6 and platelet reactivity (r = 0.199). Insulin-dependent diabetes mellitus (IDDM) was associated with higher concentration of hsIL-6 (p= .014), whereas pre-treatment with statins - with lower concentration of hsIL-6 (p= .035). In conclusion, inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in the acute phase of ACS, confirming the safety and efficacy of potent P2Y12 inhibitors in patients with a high inflammatory burden.
机译:炎症导致动脉粥样硬化和急性冠状动脉综合征(ACS)。我们进行了一项前瞻性观察性研究,以评估338名接受替卡格雷和普拉格雷治疗的ACS患者的炎症标志物(高敏C反应蛋白、hsCRP、高敏白细胞介素6、hsIL-6、可溶性CD40配体、sCD40 L)浓度与血小板反应性之间的相关性。我们还评估了hsCRP、hsIL-6和sCD40 L是否与标准炎症标志物(白细胞[WBC]和纤维蛋白原)相关,以及它们是否因患者糖尿病状态和他汀类药物治疗前的不同而不同。分别采用比浊法和酶联免疫吸附法测定hsCRP浓度、hsIL-6和sCD40 L浓度。使用多电极聚集仪测量血小板反应性。hsIL-6与血小板反应性之间只有微弱的负相关(r=0.199)。胰岛素依赖型糖尿病(IDDM)与高浓度的hsIL-6相关(p=0.014),而他汀类药物治疗前与低浓度的hsIL-6相关(p=0.035)。总之,炎症状态不影响ACS急性期有效P2Y12抑制剂的抗血小板疗效,证实了有效P2Y12抑制剂在高炎症负荷患者中的安全性和有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号